Repinex

Slide background

Want to reduce your Ropinirole XL prescribing costs by 50%?^1*

click anywhere to skip intro

*Based on 50% saving on the cost of category C ropinirole prolonged-release tablets in the UK Drug Tariff.
1) March 2017 UK Drug Tariff

Slide background

Prescribing

click anywhere to skip intro

will achieve a 50% saving on the cost of ropinirole in Category C of the Drug Tariff ^1*

*Based on 50% saving on the cost of category C ropinirole prolonged-release tablets in the UK Drug Tariff.
1) March 2017 UK Drug Tariff

Slide background

Plus...

click anywhere to skip intro

• Available from mainline wholesalers – high level of stockholdings

• Price guaranteed till 2019^**

• Bioequivalent to the originator brand²

*Based on 50% saving on the cost of category C ropinirole prolonged-release tablets in the UK Drug Tariff. ** No change in price subject to no material change to the products or Category C of the UK Drug Tariff until the 2019 PPRS review, regardless of competitor activity. 1) March 2017 UK Drug Tariff 2) Data on file, 1010067149 V 1.0 June 2016

click anywhere to skip intro

Slide background

Please enter the site for more information

click here

*Based on 50% saving on the cost of category C ropinirole prolonged-release tablets in the UK Drug Tariff.
1) March 2017 UK Drug Tariff

Repinex, ropinirole XL, ropinirole prolonged release, ropinirole 2mg, ropinirole 4mg, ropinirole 8mg, ropinirole, Parkinson’s disease, levodopa adjunct, monotherapy Parkinson’s disease, levodopa, branded generic, category C drug tariff ropinirole, Aspire Pharma, UK. Repinex XL is a ropinirole prolonged-release tablet available in the UK from Aspire Pharma as three strengths, 2, 4 and 8mg. Repinex XL can be used as an initial monotherapy or in combination with levodopa for the treatment of Parkinson’s disease. By prescribing Repinex XL the NHS could save 50% of their prescribing costs for ropinirole XL. Available in the UK from Aspire Pharma, Repinex XL is a once daily ropinirole treatment for Parkinson’s disease as a monotherapy or adjunct to levodopa.

Revision reference – Repinex XL_16_11/01/2019